Pache.co Information Technologies

Author Contributions

All authors made a significant contribution to the work reported, whether that is in the conception, study design, execution, acquisition of data, analysis and interpretation, or in all these areas; took part in drafting, revising or critically reviewing the article; gave final approval of the version to be published; have agreed on the journal to which the article has been submitted; and agree to be accountable for all aspects of the work.

This research was funded by the Doctoral Research Initiation Fund of the Affiliated Hospital of Southwest Medical University (No. 18061), the Fund for High-level Talents in Luzhou City (No. 02/00180117).

1. Andres MP, Arcoverde FVL, Souza CCC, Fernandes LFC, Abrão MS, Kho RM. Extrapelvic endometriosis: a systematic review. J Minim Invasive Gynecol. 2020;27(2):373–389. doi:10.1016/j.jmig.2019.10.004

2. Zondervan KT, Becker CM, Missmer SA, Longo DL. Endometriosis. N Engl J Med. 2020;382(13):1244–1256. doi:10.1056/NEJMra1810764

3. Garcia-Fernandez J, García-Velasco JA. Endometriosis and reproduction: what we have learned. Yale J Biol Med. 2020;93(4):571–577.

4. Prosperi Porta R, Sangiuliano C, Cavalli A, et al. Effects of breastfeeding on endometriosis-related pain: a prospective observational study. Int J Environ Res Public Health. 2021;18(20):10602. doi:10.3390/ijerph182010602

5. Armour M, Lawson K, Wood A, Smith CA, Abbott J, Thumbikat P. The cost of illness and economic burden of endometriosis and chronic pelvic pain in Australia: a national online survey. PLoS One. 2019;14(10):e0223316. doi:10.1371/journal.pone.0223316

6. Halici BNA, Aktoz F, Kabakci M, Kiran G, Ozcan P. Analysis of preoperative and postoperative quality of life, sexual function, and sleep in patients with endometriosis: a prospective cohort study. Arch Gynecol Obstet. 2022;307(1):113–120. doi:10.1007/s00404-022-06562-9

7. Kim HS, Kim TH, Chung HH, Song YS. Risk and prognosis of ovarian cancer in women with endometriosis: a meta-analysis. Br J Cancer. 2014;110(7):1878–1890. doi:10.1038/bjc.2014.29

8. Kajiyama H, Suzuki S, Yoshihara M, et al. Endometriosis and cancer. Free Radic Biol Med. 2019;133:186–192. doi:10.1016/j.freeradbiomed.2018.12.015

9. Kalaitzopoulos DR, Samartzis N, Kolovos GN, et al. Treatment of endometriosis: a review with comparison of 8 guidelines. BMC Womens Health. 2021;21(1):397. doi:10.1186/s12905-021-01545-5

10. Qin Z, Dong Z, Liu J, et al. A preliminary study on the effects of black cohosh preparations on bone metabolism of rat models with GnRH-a-induced peri-menopausal symptoms. Front Endocrinol. 2022;13:854345. doi:10.3389/fendo.2022.854345

11. Chen J, Wang H, Dong Z, et al. GnRH-a-induced perimenopausal rat modeling and black cohosh preparations’ effect on rat’s reproductive endocrine. Front Endocrinol. 2021;12:683552. doi:10.3389/fendo.2021.683552

12. Corte LD, Noventa M, Ciebiera M, et al. Phytotherapy in endometriosis: an up-to-date review. J Complement Integr Med. 2020;17(3). doi:10.1515/jcim-2019-0084

13. Zakhari A, Delpero E, McKeown S, Tomlinson G, Bougie O, Murji A. Endometriosis recurrence following post-operative hormonal suppression: a systematic review and meta-analysis. Hum Reprod Update. 2021;27(1):96–107. doi:10.1093/humupd/dmaa033

14. Guo SW. Recurrence of endometriosis and its control. Hum Reprod Update. 2009;15(4):441–461. doi:10.1093/humupd/dmp007

15. Mikus M, Vitale SG, Coric M, et al. State of the art, new treatment strategies, and emerging drugs for non-hormonal treatment of endometriosis: a systematic review of randomized control trials. Gynecol Endocrinol. 2022;38(11):911–917. doi:10.1080/09513590.2022.2133105

16. Malaguarnera L. Influence of resveratrol on the immune response. Nutrients. 2019;11(5):946. doi:10.3390/nu11050946

17. Yuan L, Zhou M, Huang D, et al. Resveratrol inhibits the invasion and metastasis of colon cancer through reversal of epithelial‑ mesenchymal transition via the AKT/GSK‑3β/Snail signaling pathway. Mol Med Rep. 2019;20(3):2783–2795. doi:10.3892/mmr.2019.10528

18. Galiniak S, Aebisher D, Bartusik-Aebisher D. Health benefits of resveratrol administration. Acta Biochim Pol. 2019;66(1):13–21. doi:10.18388/abp.2018_2749

19. Kasiotis KM, Pratsinis H, Kletsas D, Haroutounian SA. Resveratrol and related stilbenes: their anti-aging and anti-angiogenic properties. Food Chem Toxicol. 2013;61:112–120. doi:10.1016/j.fct.2013.03.038

20. Rodríguez-Enríquez S, Pacheco-Velázquez SC, Marín-Hernández Á, et al. Resveratrol inhibits cancer cell proliferation by impairing oxidative phosphorylation and inducing oxidative stress. Toxicol Appl Pharmacol. 2019;370:65–77. doi:10.1016/j.taap.2019.03.008

21. Fu X, Li M, Tang C, Huang Z, Najafi M. Targeting of cancer cell death mechanisms by resveratrol: a review. Apoptosis. 2021;26(11–12):561–573. doi:10.1007/s10495-021-01689-7

22. Burns J, Yokota T, Ashihara H, Lean ME, Crozier A. Plant foods and herbal sources of resveratrol. J Agric Food Chem. 2002;50(11):3337–3340. doi:10.1021/jf0112973

23. Sales JM, Resurreccion AV. Resveratrol in peanuts. Crit Rev Food Sci Nutr. 2014;54(6):734–770. doi:10.1080/10408398.2011.606928

24. Lyons MM, Yu C, Toma RB, et al. Resveratrol in raw and baked blueberries and bilberries. J Agric Food Chem. 2003;51(20):5867–5870. doi:10.1021/jf034150f

25. Sanders TH, McMichael RW Jr, Hendrix KW. Occurrence of resveratrol in edible peanuts. J Agric Food Chem. 2000;48(4):1243–1246. doi:10.1021/jf990737b

26. Shi J, Zeng Q, Liu Y, Pan Z. Alternaria sp. MG1, a resveratrol-producing fungus: isolation, identification, and optimal cultivation conditions for resveratrol production. Appl Microbiol Biotechnol. 2012;95(2):369–379. doi:10.1007/s00253-012-4045-9

27. Chen X, He H, Wang G, et al. Stereospecific determination of cis- and trans-resveratrol in rat plasma by HPLC: application to pharmacokinetic studies. Biomed Chromatogr. 2007;21(3):257–265. doi:10.1002/bmc.747

28. Camont L, Cottart CH, Rhayem Y, et al. Simple spectrophotometric assessment of the trans-/cis-resveratrol ratio in aqueous solutions. Anal Chim Acta. 2009;634(1):121–128. doi:10.1016/j.aca.2008.12.003

29. Salehi B, Mishra AP, Nigam M, et al. Resveratrol: a double-edged sword in health benefits. Biomedicines. 2018;6(3). doi:10.3390/biomedicines6030091

30. Caruso F, Tanski J, Villegas-Estrada A, Rossi M. Structural basis for antioxidant activity of trans-resveratrol: ab initio calculations and crystal and molecular structure. J Agric Food Chem. 2004;52(24):7279–7285. doi:10.1021/jf048794e

31. Ovesná Z, Horváthová-Kozics K. Structure-activity relationship of trans-resveratrol and its analogues. Neoplasma. 2005;52(6):450–455.

32. Carter LG, D’Orazio JA, Pearson KJ. Resveratrol and cancer: focus on in vivo evidence. Endocr Relat Cancer. 2014;21(3):R209–R225. doi:10.1530/erc-13-0171

33. Zaffaroni N, Beretta GL. Resveratrol and prostate cancer: the power of phytochemicals. Curr Med Chem. 2021;28(24):4845–4862. doi:10.2174/0929867328666201228124038

34. Vernousfaderani EK, Akhtari N, Rezaei S, et al. Resveratrol and colorectal cancer: a molecular approach to clinical researches. Curr Top Med Chem. 2021;21(29):2634–2646. doi:10.2174/1568026621666211105093658

35. Sun X, Fu P, Xie L, et al. Resveratrol inhibits the progression of cervical cancer by suppressing the transcription and expression of HPV E6 and E7 genes. Int J Mol Med. 2021;47(1):335–345. doi:10.3892/ijmm.2020.4789

36. Wu JM, Hsieh TC. Resveratrol: a cardioprotective substance. Ann N Y Acad Sci. 2011;1215:16–21. doi:10.1111/j.1749-6632.2010.05854.x

37. Tan CS, Loh YC, Tew WY, Yam MF. Vasorelaxant effect of 3,5,4’-trihydroxy-trans-stilbene (resveratrol) and its underlying mechanism. Inflammopharmacology. 2020;28(4):869–875. doi:10.1007/s10787-019-00682-6

38. Rocha-González HI, Ambriz-Tututi M, Granados-Soto V. Resveratrol: a natural compound with pharmacological potential in neurodegenerative diseases. CNS Neurosci Ther. 2008;14(3):234–247. doi:10.1111/j.1755-5949.2008.00045.x

39. Amaya SC, Savaris RF, Filipovic CJ, et al. Resveratrol and endometrium: a closer look at an active ingredient of red wine using in vivo and in vitro models. Reprod Sci. 2014;21(11):1362–1369. doi:10.1177/1933719114525271

40. Saliba C, Jaafoury H, El Hajj M, Nicolas G, Haidar Ahmad H. Abdominal wall endometriosis: a case report. Cureus. 2019;11(2):e4061. doi:10.7759/cureus.4061

41. Janša V, Klančič T, Pušić M, et al. Proteomic analysis of peritoneal fluid identified COMP and TGFBI as new candidate biomarkers for endometriosis. Sci Rep. 2021;11(1):20870. doi:10.1038/s41598-021-00299-2

42. Jiang L, Wan Y, Feng Z, et al. Long noncoding RNA UCA1 is related to autophagy and apoptosis in endometrial stromal cells. Front Oncol. 2020;10:618472. doi:10.3389/fonc.2020.618472

43. Azam INA, Wahab NA, Mokhtar MH, Shafiee MN, Mokhtar NM. Roles of microRNAs in regulating apoptosis in the pathogenesis of endometriosis. Life. 2022;12(9):1321. doi:10.3390/life12091321

44. Yerlikaya G, Balendran S, Pröstling K, et al. Comprehensive study of angiogenic factors in women with endometriosis compared to women without endometriosis. Eur J Obstet Gynecol Reprod Biol. 2016;204:88–98. doi:10.1016/j.ejogrb.2016.07.500

45. Ahn SH, Monsanto SP, Miller C, Singh SS, Thomas R, Tayade C. Pathophysiology and immune dysfunction in endometriosis. Biomed Res Int. 2015;2015:795976. doi:10.1155/2015/795976

46. Filip L, Duică F, Prădatu A, et al. Endometriosis associated infertility: a critical review and analysis on etiopathogenesis and therapeutic approaches. Medicina. 2020;56(9):460. doi:10.3390/medicina56090460

47. Clower L, Fleshman T, Geldenhuys WJ, Santanam N. Targeting oxidative stress involved in endometriosis and its pain. Biomolecules. 2022;12(8):1055. doi:10.3390/biom12081055

48. Till SR, Nakamura R, Schrepf A, As-Sanie S. Approach to diagnosis and management of chronic pelvic pain in women: incorporating chronic overlapping pain conditions in assessment and management. Obstet Gynecol Clin North Am. 2022;49(2):219–239. doi:10.1016/j.ogc.2022.02.006

49. Crain DA, Janssen SJ, Edwards TM, et al. Female reproductive disorders: the roles of endocrine-disrupting compounds and developmental timing. Fertil Steril. 2008;90(4):911–940. doi:10.1016/j.fertnstert.2008.08.067

50. Sophonsritsuk A, Tantanavipas S, Tingthanatikul Y, Lertvikool S, Dittharot K, Waiyaput W. Effects of ethinyl estradiol in combined oral contraceptives on cell proliferation and apoptosis in ectopic endometrial tissue: a randomized controlled study. J Fam Reprod Health. 2021;15(1):45–52. doi:10.18502/jfrh.v15i1.6077

51. Bruner-Tran KL, Osteen KG, Taylor HS, Sokalska A, Haines K, Duleba AJ. Resveratrol inhibits development of experimental endometriosis in vivo and reduces endometrial stromal cell invasiveness in vitro. Biol Reprod. 2011;84(1):106–112. doi:10.1095/biolreprod.110.086744

52. Rudzitis-Auth J, Menger MD, Laschke MW. Resveratrol is a potent inhibitor of vascularization and cell proliferation in experimental endometriosis. Hum Reprod. 2013;28(5):1339–1347. doi:10.1093/humrep/det031

53. Delbandi AA, Mahmoudi M, Shervin A, Heidari S, Kolahdouz-Mohammadi R, Zarnani AH. Evaluation of apoptosis and angiogenesis in ectopic and eutopic stromal cells of patients with endometriosis compared to non-endometriotic controls. BMC Womens Health. 2020;20(1):3. doi:10.1186/s12905-019-0865-4

54. Wei WD, Ruan F, Tu FX, Zhou CY, Lin J. Expression of suppressor of cytokine signaling-3 and caspase-3 in endometriosis and their correlation. Zhonghua Bing Li Xue Za Zhi. 2013;42(8):515–518. doi:10.3760/cma.j.issn.0529-5807.2013.08.003

55. Madanes D, Meresman G, Valla SA, et al. Resveratrol impairs cellular mechanisms associated with the pathogenesis of endometriosis. Reprod Biomed Online. 2022;44(6):976–990. doi:10.1016/j.rbmo.2022.02.008

56. Fan YZ, Zhang JT, Yang HC, Yang YQ. Expression of MMP-2, TIMP-2 protein and the ratio of MMP-2/TIMP-2 in gallbladder carcinoma and their significance. World J Gastroenterol. 2002;8(6):1138–1143. doi:10.3748/wjg.v8.i6.1138

57. Khazaei MR, Rashidi Z, Chobsaz F, Niromand E, Khazaei M. Inhibitory effect of resveratrol on the growth and angiogenesis of human endometrial tissue in an in vitro three-dimensional model of endometriosis. Reprod Biol. 2020;20(4):484–490. doi:10.1016/j.repbio.2020.07.012

58. Kolahdouz-Mohammadi R, Delbandi AA, Khodaverdi S, Arefi S, Arablou T, Shidfar F. The effects of resveratrol treatment on Bcl-2 and bax gene expression in endometriotic compared with non-endometriotic stromal cells. Iran J Public Health. 2020;49(8):1546–1554. doi:10.18502/ijph.v49i8.3900

59. Taguchi A, Koga K, Kawana K, et al. Resveratrol enhances apoptosis in endometriotic stromal cells. Am J Reprod Immunol. 2016;75(4):486–492. doi:10.1111/aji.12489

60. Dull AM, Moga MA, Dimienescu OG, Sechel G, Burtea V, Anastasiu CV. Therapeutic approaches of resveratrol on endometriosis via anti-inflammatory and anti-angiogenic pathways. Molecules. 2019;24(4):667. doi:10.3390/molecules24040667

61. Burney RO, Giudice LC. Pathogenesis and pathophysiology of endometriosis. Fertil Steril. 2012;98(3):511–519. doi:10.1016/j.fertnstert.2012.06.029

62. Thanatsis N, Filindris T, Siampalis A, et al. The effect of novel medical nonhormonal treatments on the angiogenesis of endometriotic lesions. Obstet Gynecol Surv. 2021;76(5):281–291. doi:10.1097/ogx.0000000000000888

63. Rocha ALL, Reis FM, Taylor RN. Angiogenesis and endometriosis. Obstet Gynecol Int. 2013;2013:859619. doi:10.1155/2013/859619

64. Folkman J. Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med. 1995;1(1):27–31. doi:10.1038/nm0195-27

65. Chung AS, Ferrara N. Developmental and pathological angiogenesis. Annu Rev Cell Dev Biol. 2011;27(1):563–584. doi:10.1146/annurev-cellbio-092910-154002

66. McMahon G. VEGF receptor signaling in tumor angiogenesis. oncologist. 2000;5(Suppl 1):3–10. doi:10.1634/theoncologist.5-suppl_1-3

67. Apte RS, Chen DS, Ferrara N. VEGF in signaling and disease: beyond discovery and development. Cell. 2019;176(6):1248–1264. doi:10.1016/j.cell.2019.01.021

68. Mahnke JL, Dawood MY, Huang JC. Vascular endothelial growth factor and interleukin-6 in peritoneal fluid of women with endometriosis. Fertil Steril. 2000;73(1):166–170. doi:10.1016/s0015-0282(99)00466-5

69. Machado DE, Abrao MS, Berardo PT, Takiya CM, Nasciutti LE. Vascular density and distribution of vascular endothelial growth factor (VEGF) and its receptor VEGFR-2 (Flk-1) are significantly higher in patients with deeply infiltrating endometriosis affecting the rectum. Fertil Steril. 2008;90(1):148–155. doi:10.1016/j.fertnstert.2007.05.076

70. Bourlev V, Volkov N, Pavlovitch S, Lets N, Larsson A, Olovsson M. The relationship between microvessel density, proliferative activity and expression of vascular endothelial growth factor-A and its receptors in eutopic endometrium and endometriotic lesions. Reproduction. 2006;132(3):501–509. doi:10.1530/rep.1.01110

71. Potlog-Nahari C, Stratton P, Winkel C, et al. Urine vascular endothelial growth factor-A is not a useful marker for endometriosis. Fertil Steril. 2004;81(6):1507–1512. doi:10.1016/j.fertnstert.2003.10.040

72. Young VJ, Ahmad SF, Duncan WC, Horne AW. The role of TGF-β in the pathophysiology of peritoneal endometriosis. Hum Reprod Update. 2017;23(5):548–559. doi:10.1093/humupd/dmx016

73. Young VJ, Brown JK, Maybin J, Saunders PT, Duncan WC, Horne AW. Transforming growth factor-β induced Warburg-like metabolic reprogramming may underpin the development of peritoneal endometriosis. J Clin Endocrinol Metab. 2014;99(9):3450–3459. doi:10.1210/jc.2014-1026

74. Young VJ, Brown JK, Saunders PT, Duncan WC, Horne AW, Dettman R. The peritoneum is both a source and target of TGF-β in women with endometriosis. PLoS One. 2014;9(9):e106773. doi:10.1371/journal.pone.0106773

75. Ricci AG, Olivares CN, Bilotas MA, et al. Natural therapies assessment for the treatment of endometriosis. Hum Reprod. 2013;28(1):178–188. doi:10.1093/humrep/des369

76. Cenksoy PO, Oktem M, Erdem O, et al. A potential novel treatment strategy: inhibition of angiogenesis and inflammation by resveratrol for regression of endometriosis in an experimental rat model. Gynecol Endocrinol. 2015;31(3):219–224. doi:10.3109/09513590.2014.976197

77. Bayoglu Tekin Y, Guven S, Kirbas A, Kalkan Y, Tumkaya L, Guvendag Guven ES. Is resveratrol a potential substitute for leuprolide acetate in experimental endometriosis? Eur J Obstet Gynecol Reprod Biol. 2015;184:1–6. doi:10.1016/j.ejogrb.2014.10.041

78. Ergenoğlu AM, Yeniel A, Erbaş O, et al. Regression of endometrial implants by resveratrol in an experimentally induced endometriosis model in rats. Reprod Sci. 2013;20(10):1230–1236. doi:10.1177/1933719113483014

79. Bahrami A, Ayen E, Razi M, Behfar M. Effects of atorvastatin and resveratrol against the experimental endometriosis; evidence for glucose and monocarboxylate transporters, neoangiogenesis. Life Sci. 2021;272:119230. doi:10.1016/j.lfs.2021.119230

80. Arablou T, Aryaeian N, Khodaverdi S, et al. The effects of resveratrol on the expression of VEGF, TGF-β, and MMP-9 in endometrial stromal cells of women with endometriosis. Sci Rep. 2021;11(1):6054. doi:10.1038/s41598-021-85512-y

81. Arablou T, Delbandi AA, Khodaverdi S, et al. Resveratrol reduces the expression of insulin-like growth factor-1 and hepatocyte growth factor in stromal cells of women with endometriosis compared with nonendometriotic women. Phytother Res. 2019;33(4):1044–1054. doi:10.1002/ptr.6298

82. Khodarahmian M, Amidi F, Moini A, et al. A randomized exploratory trial to assess the effects of resveratrol on VEGF and TNF-α 2 expression in endometriosis women. J Reprod Immunol. 2021;143(2021):103248. doi:10.1016/j.jri.2020.103248

83. Lukács L, Kovács AR, Pál L, Szűcs S, Lampé R. Evaluating the phagocytic index of peripheral leukocytes in endometriosis by plasma experiments. Medicina. 2022;58(7):925. doi:10.3390/medicina58070925

84. Yuan DP, Gu L, Long J, et al. Shikonin reduces endometriosis by inhibiting RANTES secretion and mononuclear macrophage chemotaxis. Exp Ther Med. 2014;7(3):685–690. doi:10.3892/etm.2013.1458

85. Tamai H, Kinugasa M, Nishio M, Miyake M. Peritoneal inclusion cysts treated with a levonorgestrel-releasing intrauterine system: a case report. Case Rep Womens Health. 2019;22:e00113. doi:10.1016/j.fertnstert.2008.08.067

86. Kolahdouz-Mohammadi R, Shidfar F, Khodaverdi S, et al. Resveratrol treatment reduces expression of MCP-1, IL-6, IL-8 and RANTES in endometriotic stromal cells. J Cell Mol Med. 2021;25(2):1116–1127. doi:10.1111/jcmm.16178

87. Chopyak VV, Koval HD, Havrylyuk AM, Lishchuk-Yakymovych KA, Potomkina HA, Kurpisz MK. Immunopathogenesis of endometriosis – a novel look at an old problem. Cent Eur J Immunol. 2022;47(1):109–116. doi:10.5114/ceji.2022.113830

88. Liu Y, Wang J, Zhang X. An update on the multifaceted role of NF-kappaB in endometriosis. Int J Biol Sci. 2022;18(11):4400–4413. doi:10.7150/ijbs.72707

89. Li MZ, Wu YH, Ali M, Wu XQ, Nie MF. Endometrial stromal cells treated by tumor necrosis factor-α stimulate macrophages polarized toward M2 via interleukin-6 and monocyte chemoattractant protein-1. J Obstet Gynaecol Res. 2020;46(2):293–301. doi:10.1111/jog.14135

90. Bacci M, Capobianco A, Monno A, et al. Macrophages are alternatively activated in patients with endometriosis and required for growth and vascularization of lesions in a mouse model of disease. Am J Pathol. 2009;175(2):547–556. doi:10.2353/ajpath.2009.081011

91. Wang C, Chen Z, Zhao X, et al. Transcriptome-based analysis reveals therapeutic effects of resveratrol on endometriosis in arat model. Drug Des Devel Ther. 2021;15:4141–4155. doi:10.2147/DDDT.S323790

92. Singh S, Anshita D, Ravichandiran V. MCP-1: function, regulation, and involvement in disease. Int Immunopharmacol. 2021;101(PtB):107598. doi:10.1016/j.intimp.2021.107598

93. Borrelli GM, Abrão MS, Mechsner S. Can chemokines be used as biomarkers for endometriosis? A systematic review. Hum Reprod. 2014;29(2):253–266. doi:10.1093/humrep/det401

94. Heidari S, Kolahdouz-Mohammadi R, Khodaverdi S, Tajik N, Delbandi AA. Expression levels of MCP-1, HGF, and IGF-1 in endometriotic patients compared with non-endometriotic controls. BMC Womens Health. 2021;21(1):422. doi:10.1186/s12905-021-01560-6

95. Kang YJ, Jeung IC, Park A, et al. An increased level of IL-6 suppresses NK cell activity in peritoneal fluid of patients with endometriosis via regulation of SHP-2 expression. Hum Reprod. 2014;29(10):2176–2189. doi:10.1093/humrep/deu172

96. Song Y, Su RW, Joshi NR, et al. Interleukin-6 (IL-6) activates the NOTCH1 signaling pathway through E-proteins in endometriotic lesions. J Clin Endocrinol Metab. 2020;105(5):1316–1326. doi:10.1210/clinem/dgaa096

97. Piva M, Horowitz GM, Sharpe-Timms KL. Interleukin-6 differentially stimulates haptoglobin production by peritoneal and endometriotic cells in vitro: a model for endometrial-peritoneal interaction in endometriosis. J Clin Endocrinol Metab. 2001;86(6):2553–2561. doi:10.1210/jcem.86.6.7613

98. Carmona F, Chapron C, Martínez-Zamora M, et al. Ovarian endometrioma but not deep infiltrating endometriosis is associated with increased serum levels of interleukin-8 and interleukin-6. J Reprod Immunol. 2012;95(1–2):80–86. doi:10.1016/j.jri.2012.06.001

99. Li C, Zhao HL, Li YJ, et al. The expression and significance of leukemia inhibitory factor, interleukin-6 and vascular endothelial growth factor in Chinese patients with endometriosis. Arch Gynecol Obstet. 2021;304(1):163–170. doi:10.1007/s00404-021-05980-5

100. Delbandi AA, Mahmoudi M, Shervin A, et al. Eutopic and ectopic stromal cells from patients with endometriosis exhibit differential invasive, adhesive, and proliferative behavior. Fertil Steril. 2013;100(3):761–769. doi:10.1016/j.fertnstert.2013.04.041

101. Arici A, Tazuke SI, Attar E, Kliman HJ, Olive DL. Interleukin-8 concentration in peritoneal fluid of patients with endometriosis and modulation of interleukin-8 expression in human mesothelial cells. Mol Hum Reprod. 1996;2(1):40–45. doi:10.1093/molehr/2.1.40

102. Santegoets KC, Wenink MH, van den Berg WB, Radstake TR, Bayry J. Fc gamma receptor IIb on GM-CSF macrophages controls immune complex mediated inhibition of inflammatory signals. PLoS One. 2014;9(10):e110966. doi:10.1371/journal.pone.0110966

103. Zhong YC, Zhou XF, Hou CM, Li WP. Effect of danefukang on symptoms and biomarkers in women with endometriosis. Taiwan J Obstet Gynecol. 2019;58(2):218–222. doi:10.1016/j.tjog.2019.01.009

104. Riccio LDGC, Santulli P, Marcellin L, Abrão MS, Batteux F, Chapron C. Immunology of endometriosis. Best Pract Res Clin Obstet Gynaecol. 2018;50:39–49. doi:10.1016/j.bpobgyn.2018.01.010

105. Kodarahmian M, Amidi F, Moini A, et al. The modulating effects of resveratrol on the expression of MMP-2 and MMP-9 in endometriosis women: a randomized exploratory trial. Gynecol Endocrinol. 2019;35(8):719–726. doi:10.1080/09513590.2019.1576612

106. Chu H, Li H, Guan X, et al. Resveratrol protects late endothelial progenitor cells from TNF-α-induced inflammatory damage by upregulating Krüppel-like factor-2. Mol Med Rep. 2018;17(4):5708–5715. doi:10.3892/mmr.2018.8621

107. Yu H, Pan C, Zhao S, Wang Z, Zhang H, Wu W. Resveratrol inhibits tumor necrosis factor-alpha-mediated matrix metalloproteinase-9 expression and invasion of human hepatocellular carcinoma cells. Biomed Pharmacother. 2008;62(6):366–372. doi:10.1016/j.biopha.2007.09.006

108. Morita Y, Wada-Hiraike O, Yano T, et al. Resveratrol promotes expression of SIRT1 and StAR in rat ovarian granulosa cells: an implicative role of SIRT1 in the ovary. Reprod Biol Endocrinol. 2012;10(1):14. doi:10.1186/1477-7827-10-14

109. Singh UP, Singh NP, Singh B, et al. Resveratrol (trans-3,5,4’-trihydroxystilbene) induces silent mating type information regulation-1 and down-regulates nuclear transcription factor-kappaB activation to abrogate dextran sulfate sodium-induced colitis. J Pharmacol Exp Ther. 2010;332(3):829–839. doi:10.1124/jpet.109.160838

110. Kiernan R, Brès V, Ng RW, et al. Post-activation turn-off of NF-kappa B-dependent transcription is regulated by acetylation of p65. J Biol Chem. 2003;278(4):2758–2766. doi:10.1074/jbc.M209572200

111. Mehri F, Ranjbar A, Shirafkan N, Asl SS, Esfahani M. The protective effect of resveratrol on diazinon-induced oxidative stress and glucose hemostasis disorder in rats’ liver. J Biochem Mol Toxicol. 2022;37(7):e23063. doi:10.1002/jbt.23063

112. Taguchi A, Wada-Hiraike O, Kawana K, et al. Resveratrol suppresses inflammatory responses in endometrial stromal cells derived from endometriosis: a possible role of the sirtuin 1 pathway. J Obstet Gynaecol Res. 2014;40(3):770–778. doi:10.1111/jog.12252

113. Lai ZZ, Yang HL, Ha SY, et al. Cyclooxygenase-2 in endometriosis. Int J Biol Sci. 2019;15(13):2783–2797. doi:10.7150/ijbs.35128

114. Cai X, Liu M, Zhang B, Zhao SJ, Jiang SW. Phytoestrogens for the management of endometriosis: findings and issues. Pharmaceuticals. 2021;14(6). doi:10.3390/ph14060569

115. Nanda A, Thangapandi K, Banerjee P, et al. Cytokines, angiogenesis, and extracellular matrix degradation are augmented by oxidative stress in endometriosis. Ann Lab Med. 2020;40(5):390–397. doi:10.3343/alm.2020.40.5.390

116. Maia JH, Haddad C, Pinheiro N, Casoy J. Advantages of the association of resveratrol with oral contraceptives for management of endometriosis-related pain. Int J Womens Health. 2012;4(1):543–549. doi:10.2147/IJWH.S36825

117. da Silva DM, Gross LA, Neto EPG, Lessey BA, Savaris RF. The use of resveratrol as an adjuvant treatment of pain in endometriosis: a randomized clinical trial. J Endocrinol Soc. 2017;1(4):359–369. doi:10.1210/js.2017-00053

118. Cacciottola L, Donnez J, Dolmans MM. Can endometriosis-related oxidative stress pave the way for new treatment targets? Int J Mol Sci. 2021;22(13):7138. doi:10.3390/ijms22137138

119. Lingappan K. NF-κB in oxidative stress. Curr Opin Toxicol. 2018;7:81–86. doi:10.1016/j.cotox.2017.11.002

120. Van Langendonckt A, Casanas-Roux F, Donnez J. Oxidative stress and peritoneal endometriosis. Fertil Steril. 2002;77(5):861–870. doi:10.1016/S0015-0282(02)02959-X

121. Gupta S, Agarwal A, Krajcir N, Alvarez JG. Role of oxidative stress in endometriosis. Reprod Biomed Online. 2006;13(1):126–134. 2291. doi:10.1016/S1472-6483(10)62026-3

122. Bach Knudsen KE, Lærke HN, Hedemann MS, et al. Impact of diet-modulated butyrate production on intestinal barrier function and inflammation. Nutrients. 2018;10(10):1499. doi:10.3390/nu10101499

123. González-Ramos R, Donnez J, Defrère S, et al. Nuclear factor-kappa B is constitutively activated in peritoneal endometriosis. Mol Hum Reprod. 2007;13(7):503–509. doi:10.1093/molehr/gam033

124. Vallée A, Lecarpentier Y. Curcumin and endometriosis. Int J Mol Sci. 2020;21(7):2440. doi:10.3390/ijms21072440

125. Qiu XM, Lai ZZ, Ha SY, et al. IL-2 and IL-27 synergistically promote growth and invasion of endometriotic stromal cells by maintaining the balance of IFN-γ and IL-10 in endometriosis. Reproduction. 2020;159(3):251–260. doi:10.1530/rep-19-0411

126. Liu P, Pan Q. Butein inhibits oxidative stress injury in rats with chronic heart failure via ERK/Nrf2 signaling. Cardiovasc Ther. 2022;2022:8684014. doi:10.1155/2022/8684014

127. Yavuz S, Aydin N, Celik O, Yilmaz E, Ozerol E, Tanbek K. Resveratrol successfully treats experimental endometriosis through modulation of oxidative stress and lipid peroxidation. J Cancer Res. 2014;10(2):324–329. doi:10.4103/0973-1482.136619

128. Sampson JA. Peritoneal endometriosis due to the menstrual dissemination of endometrial tissue into the peritoneal cavity. Am J Obstet Gynecol. 1927;14:422–469. doi:10.1016/S0002-9378(15)30003-X

129. Jana S, Rudra DS, Paul S, Swarnakar S. Curcumin delays endometriosis development by inhibiting MMP-2 activity. Indian J Biochem Biophys. 2012;49(5):342–348.

130. Vihinen P, Ala-Aho R, Kähäri VM. Matrix metalloproteinases as therapeutic targets in cancer. Curr Cancer Drug Targets. 2005;5(3):203–220. doi:10.2174/1568009053765799

131. Zakiyanov O, Kalousová M, Zima T, Tesař V. Matrix metalloproteinases in renal diseases: a critical appraisal. Kidney Blood Press Res. 2019;44(3):298–330. doi:10.1159/000499876

132. Ke J, Ye J, Li M, Zhu Z. The role of matrix metalloproteinases in endometriosis: a potential target. Biomolecules. 2021;11(11):1739. doi:10.3390/biom11111739

133. Simões G, Pereira T, Caseiro A. Matrix metaloproteinases in vascular pathology. Microvasc Res. 2022;143:104398. doi:10.1016/j.mvr.2022.104398

134. Chen Z, Wang C, Lin C, et al. Lipidomic alterations and PPARα activation induced by resveratrol lead to reduction in lesion size in endometriosis models. Oxid Med Cell Longev. 2021;2021:9979953. doi:10.1155/2021/9979953

135. Lamouille S, Xu J, Derynck R. Molecular mechanisms of epithelial-mesenchymal transition. Nat Rev Mol Cell Biol. 2014;15(3):178–196. doi:10.1038/nrm3758

136. Li L, Liu J, Xue H, et al. A TGF-β-MTA1-SOX4-EZH2 signaling axis drives epithelial-mesenchymal transition in tumor metastasis. Oncogene. 2020;39(10):2125–2139. doi:10.1038/s41388-019-1132-8

137. Xu X, Kong X, Liu T, et al. Metastasis-associated protein 1, modulated by miR-30c, promotes endometrial cancer progression through AKT/mTOR/4E-BP1 pathway. Gynecol Oncol. 2019;154(1):207–217. doi:10.1016/j.ygyno.2019.04.005

138. Kong X, Xu X, Zhou L, et al. MTA1, a target of resveratrol, promotes epithelial-mesenchymal transition of endometriosis via ZEB2. Mol Ther Methods Clin Dev. 2020;19:295–306. doi:10.1016/j.omtm.2020.09.013

139. Renda G, Gökkaya İ, Şöhretoğlu D. Immunomodulatory properties of triterpenes. Phytochem Rev. 2022;21(2):537–563. doi:10.1007/s11101-021-09785-x

140. Correa FJS, Andres MP, Rocha TP, et al. Invariant natural killer T-cells and their subtypes may play a role in the pathogenesis of endometriosis. Clinics. 2022;77:100032. doi:10.1016/j.clinsp.2022.100032

141. Huhtinen K, Desai R, Ståhle M, et al. Endometrial and endometriotic concentrations of estrone and estradiol are determined by local metabolism rather than circulating levels. J Clin Endocrinol Metab. 2012;97(11):4228–4235. doi:10.1210/jc.2012-1154

142. Chantalat E, Valera MC, Vaysse C, et al. Estrogen receptors and endometriosis. Int J Mol Sci. 2020;21(8):2815. doi:10.3390/ijms21082815

143. Gołąbek A, Kowalska K, Olejnik A. Polyphenols as a diet therapy concept for endometriosis— current opinion and future perspectives. Nutrients. 2021;13(4). doi:10.3390/nu13041347

144. Houshdaran S, Oke AB, Fung JC, Vo KC, Nezhat C, Giudice LC. Steroid hormones regulate genome-wide epigenetic programming and gene transcription in human endometrial cells with marked aberrancies in endometriosis. PLoS Genet. 2020;16(6):e1008601. doi:10.1371/journal.pgen.1008601

145. Chen P, Li B, Ou-Yang L. Role of estrogen receptors in health and disease. Front Endocrinol. 2022;13:839005. doi:10.3389/fendo.2022.839005

146. Xue Q, Lin Z, Cheng YH, et al. Promoter methylation regulates estrogen receptor 2 in human endometrium and endometriosis. Biol Reprod. 2007;77(4):681–687. doi:10.1095/biolreprod.107.061804

147. Han SJ, Jung SY, Wu SP, et al. Estrogen receptor β modulates apoptosis complexes and the inflammasome to drive the pathogenesis of endometriosis. Cell. 2015;163(4):960–974. doi:10.1016/j.cell.2015.10.034

148. Yang KR, Yu HC, Huang CY, et al. Bioprocessed production of resveratrol-enriched rice wine: simultaneous rice wine fermentation, extraction, and transformation of piceid to resveratrol from Polygonum cuspidatum roots. Foods. 2019;8(7):258. doi:10.3390/foods8070258

149. Walle T. Bioavailability of resveratrol. Ann N Y Acad Sci. 2011;1215:9–15. doi:10.1111/j.1749-6632.2010.05842.x

150. Marier JF, Vachon P, Gritsas A, Zhang J, Moreau JP, Ducharme MP. Metabolism and disposition of resveratrol in rats: extent of absorption, glucuronidation, and enterohepatic recirculation evidenced by a linked-rat model. J Pharmacol Exp Ther. 2002;302(1):369–373. doi:10.1124/jpet.102.033340

151. Henry-Vitrac C, Desmoulière A, Girard D, Mérillon JM, Krisa S. Transport, deglycosylation, and metabolism of trans-piceid by small intestinal epithelial cells. Eur J Nutr. 2006;45(7):376–382. doi:10.1007/s00394-006-0609-8

152. Wenzel E, Somoza V. Metabolism and bioavailability of trans-resveratrol. Mol Nutr Food Res. 2005;49(5):472–481. doi:10.1002/mnfr.200500010

153. Singh CK, Ndiaye MA, Ahmad N. Resveratrol and cancer: challenges for clinical translation. Biochim Biophys Acta. 2015;1852(6):1178–1185. doi:10.1016/j.bbadis.2014.11.004

154. Chimento A, De Amicis F, Sirianni R, et al. Progress to improve oral bioavailability and beneficial effects of resveratrol. Int J Mol Sci. 2019;20(6):1381. doi:10.3390/ijms20061381

155. Tsai MJ, Lu IJ, Fu YS, Fang YP, Huang YB, Wu PC. Nanocarriers enhance the transdermal bioavailability of resveratrol: in-vitro and in-vivo study. Colloids Surf B Biointerfaces. 2016;148:650–656. doi:10.1016/j.colsurfb.2016.09.045

156. Lin YC, Hu SC, Huang PH, Lin TC, Yen FL. Electrospun resveratrol-loaded polyvinylpyrrolidone/cyclodextrin nanofibers and their biomedical applications. Pharmaceutics. 2020;12(6):552. doi:10.3390/pharmaceutics12060552

157. Summerlin N, Soo E, Thakur S, Qu Z, Jambhrunkar S, Popat A. Resveratrol nanoformulations: challenges and opportunities. Int J Pharm. 2015;479(2):282–290. doi:10.1016/j.ijpharm.2015.01.003

158. Guo W, Li A, Jia Z, Yuan Y, Dai H, Li H. Transferrin modified PEG-PLA-resveratrol conjugates: in vitro and in vivo studies for glioma. Eur J Pharmacol. 2013;718(1–3):41–47. doi:10.1016/j.ejphar.2013.09.034

159. Edwards JA, Beck M, Riegger C, Bausch J. Safety of resveratrol with examples for high purity, trans-resveratrol, resVida(^®). Ann N Y Acad Sci. 2011;1215:131–137. doi:10.1111/j.1749-6632.2010.05855.x

160. Zhong LX, Wu ML, Li H, Liu J, Lin LZ. Efficacy and safety of intraperitoneally administered resveratrol against rat orthotopic ovarian cancers. Cancer Manag Res. 2019;11:6113–6124. doi:10.2147/cmar.S206301

161. Szende B, Tyihák E, Király-Véghely Z. Dose-dependent effect of resveratrol on proliferation and apoptosis in endothelial and tumor cell cultures. Exp Mol Med. 2000;32(2):88–92. doi:10.1038/emm.2000.16

162. Wu H, Chen L, Zhu F, Han X, Sun L, Chen K. The cytotoxicity effect of resveratrol: cell cycle arrest and induced apoptosis of breast cancer 4T1 cells. Toxins. 2019;11(12):731. doi:10.3390/toxins11120731

163. Johnson WD, Morrissey RL, Usborne AL, et al. Subchronic oral toxicity and cardiovascular safety pharmacology studies of resveratrol, a naturally occurring polyphenol with cancer preventive activity. Food Chem Toxicol. 2011;49(12):3319–3327. doi:10.1016/j.fct.2011.08.023

164. Crowell JA, Korytko PJ, Morrissey RL, Booth TD, Levine BS. Resveratrol-associated renal toxicity. Toxicol Sci. 2004;82(2):614–619. doi:10.1093/toxsci/kfh263

165. Liu S, Zhao M, Zhou Y, et al. Resveratrol exerts dose-dependent anti-fibrotic or pro-fibrotic effects in kidneys: a potential risk to individuals with impaired kidney function. Phytomedicine. 2019;57:223–235. doi:10.1016/j.phymed.2018.12.024

166. Shaito A, Posadino AM, Younes N, et al. Potential adverse effects of resveratrol: a literature review. Int J Mol Sci. 2020;21(6):2084. doi:10.3390/ijms21062084

167. Amiot MJ, Romier B, Dao TM, et al. Optimization of trans-resveratrol bioavailability for human therapy. Biochimie. 2013;95(6):1233–1238. doi:10.1016/j.biochi.2013.01.008

168. Howells LM, Berry DP, Elliott PJ, et al. Phase I randomized, double-blind pilot study of micronized resveratrol (SRT501) in patients with hepatic metastases–safety, pharmacokinetics, and pharmacodynamics. Cancer Prev Res. 2011;4(9):1419–1425. doi:10.1158/1940-6207.Capr-11-0148

169. la Porte C, Voduc N, Zhang G, et al. Steady-state pharmacokinetics and tolerability of trans-resveratrol 2000 mg twice daily with food, quercetin and alcohol (ethanol) in healthy human subjects. Clin Pharmacokinet. 2010;49(7):449–454. doi:10.2165/11531820-000000000-00000

170. Almeida L, Vaz-da-Silva M, Falcão A, et al. Pharmacokinetic and safety profile of trans-resveratrol in a rising multiple-dose study in healthy volunteers. Mol Nutr Food Res. 2009;53(Suppl 1):S7–S15. doi:10.1002/mnfr.200800177

171. Boocock DJ, Faust GE, Patel KR, et al. Phase I dose escalation pharmacokinetic study in healthy volunteers of resveratrol, a potential cancer chemopreventive agent. Cancer Epidemiol Biomarkers Prev. 2007;16(6):1246–1252. doi:10.1158/1055-9965.Epi-07-0022

172. Sergides C, Chirilă M, Silvestro L, Pitta D, Pittas A. Bioavailability and safety study of resveratrol 500 mg tablets in healthy male and female volunteers. Exp Ther Med. 2016;11(1):164–170. doi:10.3892/etm.2015.2895

173. Singh AP, Singh R, Verma SS, et al. Health benefits of resveratrol: evidence from clinical studies. Med Res Rev. 2019;39(5):1851–1891. doi:10.1002/med.21565